Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
BUSINESS
Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
The Japan launch of Novo Nordisk’s Wegovy (semaglutide), approved earlier this year as the country’s first obesity drug in three decades, is being pushed back as the company sees “unprecedented demand” globally, local president Kasper Bødker Mejlvang said on June…
To read the full story
Related Article
- As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
- Japan Obesity Society Urges Attention to Suicidal Thoughts in Patients Who Use Wegovy
November 29, 2023
- Wegovy Lands Reimbursement Listing in Japan 8 Months after Approval
November 16, 2023
BUSINESS
- Novo Nordisk Launches Higher-Capacity Awiqli Pen in Japan
December 4, 2025
- Daiichi Sankyo Wins US Appeal in Seagen ADC Patent Dispute
December 4, 2025
- Vimpat Generics Win Added Use, Clearing Path for Full-Label Launch
December 4, 2025
- Alfresa, CMIC Ink Pact to Build Vaccination Support Platform
December 3, 2025
- Lundbeck Japan Plans to Double Workforce by 2028 as It Eyes 3 Drug Approvals
December 2, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s drug pricing panel on November 19 discussed a wide range of potential pricing changes related to patent-protected medicines, including…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…